CRDF Earnings — Cardiff Oncology, Inc. Common Stock Post-ER Performance | BigEarnings
CRDF — Cardiff Oncology, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$1.78
Market Cap$123.7M
P/E—
52W Range$1.48 – $4.55
Next Earnings2026-07-28
About Cardiff Oncology, Inc. Common Stock
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
